You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
澤璟製藥(688266.SH):2020年度虧損收窄 預虧2.95億元-3.38億元
格隆匯 01-28 18:32

格隆匯1月28日丨澤璟製藥(688266.SH)發佈2020年年度業績預吿,預計2020年度歸屬於上市公司股東的淨利潤為-3.38億元至-2.95億元,比上年同期虧損減少1.23億元到1.67億元,同比減虧26.73%到36.23%。

預計2020年度扣除非經常性損益後歸屬於上市公司股東的淨利潤為-3.79億元至-3.25億元,比上年同期虧損增加5305.05萬元到1.07億元,同比增虧19.52%到39.34%。

公司預計2020年度研發費用約2.95億元到3.26億元,比上年同期增長1.11億元到1.42億元,同比增長60.46%到77.35%。

公司2020年尚無藥品獲得商業銷售批准,未產生藥品銷售收入。公司預計2020年度取得抗體產品對外授權許可收入及少量研發技術服務收入約2,572.46到2,959.72萬元,上年同期無營業收入。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account